ADVFN - Advanced Financial Network.
HOME» NYSE » A » ABT Stock Price » ABT Stock News

Abbott Labs Share News

 Abbott Laboratories Stock Price
ABT Stock Price
 Abbott Laboratories Stock Chart
ABT Stock Chart
 Abbott Laboratories Stock News
ABT Stock News
 Abbott Laboratories Company Information
ABT Company Information
 Abbott Laboratories Stock Trades
ABT Stock Trades

Abbott Labs 1Q Net Rose 44% On Strong Drug, Nutritional Sales

DOW JONES NEWSWIRES Abbott Laboratories' (ABT) first-quarter earnings rose 44% as strong drug and nutritional sales contributed to improved margins. The health-care company also raised its full-year earnings guidance by 5 cents, now projecting $5 to $5.10 a share. Abbott's diverse portfolio had cushioned it from some of the problems, like patent expirations and generic competition, facing other large drug makers. But its bottom-line performance has been mixed in recent quarters as restructuring and acquisition charges masked revenue growth. The company has been on a buying spree in recent years in order to reduce its dependence on the anti-inflammatory Humira as the drug's U.S. patent expires in late 2016. Abbott also is in the midst of separating its proprietary drug unit and medical products business into two publicly traded companies by the end of this year. Last month, Abbott named its post-spinoff pharmaceutical company AbbVie, in a nod to the new company's origins and purpose. The health-care company said the name is derived from a combination of Abbott and vie, which references the Latin root vi, meaning life. Abbott Labs reported a profit of $1.24 billion, or 78 cents a share, up from $864 million, or 55 cents, a year earlier. Excluding items such as restructuring, acquisition and integration costs, earnings rose to $1.03 a share from 91 cents. Sales jumped 4.6% to $9.46 billion. Analysts polled by Thomson Reuters had most recently forecast earnings of $1 a share on revenue of $9.37 billion. Operating margin rose to 16.7% from 14.4%. Proprietary pharmaceutical sales, the company's biggest segment by revenue, rose 7.1%. Nutritional sales, which include Similac and Ensure, grew 10%. The established products segment, which focuses on generic sales outside the U.S., saw a 1.6% sales decline. Core laboratory diagnostics sales were up 4.9%. Shares closed Tuesday at $60.43 and were inactive premarket. The stock has gained 9.2% over the past three months. -By Melodie Warner, Dow Jones Newswires; 212-416-2283;

Stock News for Abbott Labs (ABT)
10/12/201516:00:00Abbott Laboratories Dissolving Stent Shows Mixed Results
10/12/201515:57:00Abbott Laboratories Dissolving Stent Shows Mixed Results in Study
10/12/201514:25:00Abbott Announces Positive Clinical Results of Absorb™, the N...
10/12/201510:07:14Markets Soar, Markets Orbit And Markets Crash
10/09/201514:44:42Boston Arrives Late To The Mitral Valve Party
10/02/201517:11:28Statement of Changes in Beneficial Ownership (4)
10/02/201517:10:36Statement of Changes in Beneficial Ownership (4)
10/02/201517:09:18Statement of Changes in Beneficial Ownership (4)
10/02/201517:08:55Statement of Changes in Beneficial Ownership (4)
10/01/201513:00:00Abbott Celebrates Living Fully Through the Power of Health as...
09/30/201509:00:00Abbott Hosts Conference Call for Third-Quarter Earnings
09/29/201517:37:24Statement of Changes in Beneficial Ownership (4)
09/23/201509:15:00Sponsorships and Partnerships for Scheduled Events - Report...
09/22/201510:00:00What Does It Mean to Live Fully?
09/22/201508:00:00Abbott Marks 15 Years of Helping Career-Minded Moms Reach Their...
09/18/201508:30:00Medical Appliances and Equipment Stocks Technical Report -- Boston...
09/17/201509:00:00Abbott Declares 367th Consecutive Quarterly Dividend
09/16/201508:00:00Nouvelle technologie pouvant offrir une vision utile sur une...
09/16/201508:00:00New Technology Can Offer People with Cataracts a Full Range of...
09/10/201512:47:00Abbott Named Industry Leader for Responsible and Sustainable...

Abbott Laboratories and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations